If the Bonferroni corrected P > 0.05, the P-value would not be marked in the subgroup map, but from the color comparison of the corresponding patches in the subgroup map, it can be seen that the P-value of anti-CTLA4 therapy in the high-risk group is lower than that in the low-risk group, indicating that glioma patients in the high-risk group are more likely to respond to anti-CTLA4 therapy (Figure 6F and Supplementary Figure 8C–8F). Here, CTLA4 is linked to glioma.